A case report of invasive aspergillosis occurring after tocilizumab (anti–IL-6R) therapy in a patient with COVID-19 cautions against indiscriminate extrapolation of anti-IL-6/IL-8 strategies to COPD–PA (134), and many questions remain unresolved. The gene discussed is IL6; the disease is chronic obstructive pulmonary disease.